Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced updated six-month clinical data from the ongoing open-label, first-in-human Phase 1/2 study evaluating EPI-321 in patients with facioscapulohumeral muscular dystrophy (FSHD). This updated data from the first six patients enrolled in the study were presented at the 31st Annual Congress of the World Muscle Society (WMS 2026) in Hiroshima, Japan.
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD
Epicrispr Biotechnologies, a clinical-stage biotechnology company pioneering programmable epigenetic medicines, today announced the closing of a $90 million oversubscribed Series C financing co-led by Octagon Capital and Janus Henderson Investors, with participation from Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital, and existing investors.
Epicrispr Completes Enrollment and Dose Escalation in First-in-Human EPI-321 Trial for FSHD
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced the completion of enrollment and dosing in the dose-escalation portion of its first-in-human clinical trial evaluating EPI-321 for facioscapulohumeral muscular dystrophy (FSHD). All 12 patients have now been enrolled and dosed across two dose cohorts.
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from its ongoing open-label Phase 1/2 first-in-human study of EPI-321 in facioscapulohumeral muscular dystrophy (FSHD), demonstrating the first reported clinical evidence that a therapy increased muscle volume in patients with FSHD, potentially providing a disease modifying benefit.
Epicrispr Biotechnologies Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026, ranking among the top companies in the Biotech category. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions.
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing first-in-human, open-label study evaluating EPI-321, an investigational epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD).
Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that Amber Salzman, Ph.D., Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:00 a.m. PT.
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
Epicrispr Biotechnologies, a clinical-stage company pioneering gene-modulating therapies, today announced that the first patient has been dosed in its global first-in-human clinical trial of EPI-321, an investigational, one-time epigenetic editing therapy for facioscapulohumeral muscular dystrophy (FSHD).
Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has been named a Finalist Team in XPRIZE Healthspan FSHD Bonus Prize, earning a $250,000 Milestone Award for its work addressing facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy globally.
Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced five presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, being held May 15-17, 2025, in New Orleans, Louisiana. The presentations will highlight the company’s progress across key areas, including its lead epigenetic therapeutic candidate EPI-321, novel Cas effectors for epigenome engineering, and innovations in compact modular epigenetic activators.
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced a partnership with Springbok Analytics to incorporate advanced, AI-driven muscle MRI imaging and analysis into its first-in-human clinical trial of EPI-321, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD).
Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EPI-321, a first-in-class epigenetic therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, today announced it has secured $68 million in the first close of its Series B financing. The proceeds will support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease.
Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT– Company’s non-cutting technology, engineered to be even more compact and deliverable, demonstrates synergistic gene reactivation in vitro –
